Some Traders Are Very Bullish on Bellerophon Therapeutics, Inc. (BLPH) After Forming Bullish Wedge Up Chart Pattern

May 17, 2018 - By Jimmy Baldridge

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Logo

The stock of Bellerophon Therapeutics, Inc. (BLPH) formed an up wedge with $2.48 target or 4.00 % above today’s $2.38 share price. The 9 months wedge indicates low risk for the $136.54M company. If the $2.48 price target is reached, the company will be worth $5.46 million more.
Rising wedges, especially for downward breakouts are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 8% and 24%. The average rise is 28% and the decline is 14%. Wedges has high throwback and pullback rate: 73%, 63% and the percent of wedges meeting target is not more than 50%.

The stock increased 3.03% or $0.07 during the last trading session, reaching $2.38. About 356,487 shares traded or 133.66% up from the average. Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) has risen 58.74% since May 17, 2017 and is uptrending. It has outperformed by 47.19% the S&P500.

Analysts await Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) to report earnings on May, 21. They expect $-0.14 earnings per share, up 6.67 % or $0.01 from last year’s $-0.15 per share. After $-0.24 actual earnings per share reported by Bellerophon Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -41.67 % EPS growth.

More recent Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) news were published by: which released: “3 Biotech Stocks That Will Thrive Amid Market Instability” on April 19, 2018. Also published the news titled: “Bellerophon to Present Positive Results from Phase 2 Study of INOpulse® for Treatment of Pulmonary Hypertension …” on May 16, 2018.‘s news article titled: “Bellerophon Therapeutics (BLPH) Reports Agreement with FDA on Study Design of Phase 2b Trial of INOpulse for …” with publication date: May 08, 2018 was also an interesting one.

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. The company has market cap of $136.54 million. The Company’s product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: